Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 09, 2017 07:00 ET | Source: MediWound Ltd.

Favorable Results from NexoBrid Phase 2 Pharmacokinetic Clinical Study Support Treatment of Severe Burns Covering up to 30% of Total Body Surface Area

YAVNE, Israel , Feb. 09, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
February 06, 2017 07:00 ET | Source: MediWound Ltd.

MediWound Initiates Second Stage of European Pediatric Phase 3 Study of NexoBrid® Expanding Treatment of Severe Burns to Children Age One to Four

YAVNE, Israel, Feb. 06, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
January 31, 2017 07:00 ET | Source: MediWound Ltd.

MediWound Reports Final Positive Results of Phase 2 Clinical Trial of EscharEx for the Debridement of Chronic and Hard-to-Heal Wounds

YAVNE, Israel, Jan. 31, 2017 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
December 20, 2016 07:00 ET | Source: MediWound Ltd.

MediWound Granted U.S. Patent for MWPC003 for the Treatment of Connective Tissue Diseases

YAVNE, Israel, Dec. 20, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
November 18, 2016 08:00 ET | Source: MediWound Ltd.

Abstract Highlighting NexoBrid® in Burn Mass Casualties Awarded “Best Poster” at the International Disaster and Military Medicine Conference

YAVNE, Israel, Nov. 18, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
November 14, 2016 06:45 ET | Source: MediWound Ltd.

MediWound Reports Third Quarter 2016 Financial Results

YAVNE, Israel, Nov. 14, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
November 04, 2016 08:00 ET | Source: MediWound Ltd.

MediWound to Host Third Quarter 2016 Financial Results Conference Call on November 14, 2016 at 8:30 a.m. Eastern Time

YAVNE, Israel, Nov. 04, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (NASDAQ:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
November 01, 2016 16:05 ET | Source: MediWound Ltd.

MediWound to Present at the Credit Suisse 25th Annual Healthcare Conference

YAVNE, Israel, Nov. 01, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...
August 26, 2016 08:00 ET | Source: MediWound Ltd.

MediWound to Present at 11th Annual Wells Fargo Healthcare Conference

YAVNE, Israel, Aug. 26, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn...
August 24, 2016 07:00 ET | Source: MediWound Ltd.

MediWound’s NexoBrid and EscharEx to be Featured at International Society for Burn Injuries 2016

YAVNE, Israel, Aug. 24, 2016 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq:MDWD), a fully-integrated biopharmaceutical company bringing innovative therapies to address unmet needs in severe burn and...